The role of p53 in treatment responses of lung cancer

Resistance to radio- and chemotherapy is a major problem in treatment responses of lung cancer. In this disease, biological markers, that can be predictive of response to treatment for guiding clinical practice, still need to be validated. Radiotherapy and most chemotherapeutic agents directly targe...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2005-06, Vol.331 (3), p.868-880
Main Authors: Viktorsson, Kristina, De Petris, Luigi, Lewensohn, Rolf
Format: Article
Language:English
Subjects:
APOPTOSIS
BIOLOGICAL MARKERS
Biomarkers
Carcinoma, Non-Small-Cell Lung - radiotherapy
Carcinoma, Non-Small-Cell Lung - therapy
Carcinoma, Small Cell - radiotherapy
Carcinoma, Small Cell - therapy
CELL CYCLE
CHEMOTHERAPY
Combined Modality Therapy
DNA REPAIR
DNA-Binding Proteins - biosynthesis
Drug Resistance, Neoplasm
Genes, p53
Genes, Tumor Suppressor
High-LET radiation
Humans
LET
Lung cancer
Lung Neoplasms - radiotherapy
Lung Neoplasms - therapy
LUNGS
Medicin och hälsovetenskap
Mutation
MUTATION FREQUENCY
NEOPLASMS
Nuclear Proteins - biosynthesis
p53
p63
p73
Phosphoproteins - biosynthesis
Radiation Tolerance
RADIOLOGY AND NUCLEAR MEDICINE
RADIOTHERAPY
Trans-Activators - biosynthesis
Transcription Factors
Tumor Protein p73
Tumor Suppressor Protein p53 - physiology
Tumor Suppressor Proteins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Resistance to radio- and chemotherapy is a major problem in treatment responses of lung cancer. In this disease, biological markers, that can be predictive of response to treatment for guiding clinical practice, still need to be validated. Radiotherapy and most chemotherapeutic agents directly target DNA and in response to such therapies, p53 functions as a coordinator of the DNA repair process, cell cycle arrest, and apoptosis. In fact, it participates in the main DNA repair systems operative in cells, including NHEJ, HRR, NER, BER, and MMR. Given the high p53 mutation frequency in lung cancer which likely impairs some of the p53-mediated functions, a role of p53 as a predictive marker for treatment responses has been suggested. In this review, we summarize the conflicting results coming from preclinical and clinical studies on the role of p53 as a predictive marker of responses to chemotherapy or radiotherapy in lung cancer.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2005.03.192